Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Distillery Therapeutics

Inhibiting MS4A7 for MASH

BC Staff
March 26, 2024 7:59 PM UTC

Inhibiting the transmembrane protein MS4A7 could help treat metabolic dysfunction-associated steatohepatitis (MASH), also known as NASH, by decreasing NLRP3-driven adoption of pathogenic liver macrophage phenotypes in response to lipid droplets released from steatotic hepatocytes.

Single cell RNA sequencing of disease-associated, TREM2-positive macrophages from mouse livers identified MS4A7 as highly expressed in these cells during MASH. ...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

University of Michigan